Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      The University of Texas MD Anderson Cancer Center, Houston Texas
    • Subject Terms:
    • Subject Terms:
    • Abstract:
      Background: Dasatinib, a potent Bcr-Abl tyrosine kinase inhibitor, is approved for the treatment of chronic-phase chronic myeloid leukemia (CML-CP) in the frontline and salvage settings. Notable side effects include pleural effusions and myelosuppression. Dasatinib at 50 mg daily has previously been reported to be active and better tolerated than the approved 100-mg daily dose. The aim of this study was to update the long-term follow-up results of dasatinib at 50 mg daily as frontline therapy for CML-CP.Methods: Eighty-three patients with newly diagnosed CML-CP received dasatinib at 50 mg daily. Eligibility and response criteria were standards used in previous protocols.Results: After a minimum follow-up of 12 months, 81 patients were evaluable. Two patients came off the study in less than 3 months. The rates of BCR-ABL1 transcript levels (International Standard) at ≤10% and ≤1% at 3 months were 96% and 77%, respectively. The cumulative rates for a complete cytogenetic response by 6 and 12 months were 77% and 95%, respectively. The cumulative rates for a major molecular response, a molecular response with a 4.0-log reduction, and a molecular response with a 4.5-log reduction by 12 months were 81%, 55%, and 49%, respectively. Twenty-one patients (25%) had treatment interruptions for a median of 13 days (range, 4-64 days). Five patients (6%) developed pleural effusions; 4 of these patients (80%) required a dose reduction. Two patients (2%) failed to achieve any cytogenetic or molecular response and were taken off the study. At a median follow-up of 24 months, none of the patients had disease transformation to an accelerated or blastic phase. The 2-year event-free and overall survival rates were 100%.Conclusions: These updated results continue to support 50 mg of dasatinib daily as an effective and safe dose for early CML-CP.
    • Journal Subset:
      Biomedical; Peer Reviewed; USA
    • ISSN:
      0008-543X
    • MEDLINE Info:
      PMID: NLM31553487 NLM UID: 0374236
    • Grant Information:
      P30 CA016672/NH/NIH HHS/United States
    • Publication Date:
      20200627
    • Publication Date:
      20200704
    • DOI:
      10.1002/cncr.32504
    • Accession Number:
      140299210
  • Citations
    • ABNT:
      NAQVI, K. et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer (0008543X), [s. l.], v. 126, n. 1, p. 67–75, 2020. DOI 10.1002/cncr.32504. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=140299210. Acesso em: 25 set. 2020.
    • AMA:
      Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer (0008543X). 2020;126(1):67-75. doi:10.1002/cncr.32504
    • APA:
      Naqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., Jain, N., Takahashi, K., Burger, J., Estrov, Z., Borthakur, G., Pemmaraju, N., Paul, S., Cortes, J., & Kantarjian, H. M. (2020). Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer (0008543X), 126(1), 67–75. https://doi.org/10.1002/cncr.32504
    • Chicago/Turabian: Author-Date:
      Naqvi, Kiran, Elias Jabbour, Jeffrey Skinner, Kristin Anderson, Sara Dellasala, Musa Yilmaz, Alessandra Ferrajoli, et al. 2020. “Long-Term Follow-up of Lower Dose Dasatinib (50 Mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia.” Cancer (0008543X) 126 (1): 67–75. doi:10.1002/cncr.32504.
    • Harvard:
      Naqvi, K. et al. (2020) ‘Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia’, Cancer (0008543X), 126(1), pp. 67–75. doi: 10.1002/cncr.32504.
    • Harvard: Australian:
      Naqvi, K, Jabbour, E, Skinner, J, Anderson, K, Dellasala, S, Yilmaz, M, Ferrajoli, A, Bose, P, Thompson, P, Alvarado, Y, Jain, N, Takahashi, K, Burger, J, Estrov, Z, Borthakur, G, Pemmaraju, N, Paul, S, Cortes, J & Kantarjian, HM 2020, ‘Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia’, Cancer (0008543X), vol. 126, no. 1, pp. 67–75, viewed 25 September 2020, .
    • MLA:
      Naqvi, Kiran, et al. “Long-Term Follow-up of Lower Dose Dasatinib (50 Mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia.” Cancer (0008543X), vol. 126, no. 1, Jan. 2020, pp. 67–75. EBSCOhost, doi:10.1002/cncr.32504.
    • Chicago/Turabian: Humanities:
      Naqvi, Kiran, Elias Jabbour, Jeffrey Skinner, Kristin Anderson, Sara Dellasala, Musa Yilmaz, Alessandra Ferrajoli, et al. “Long-Term Follow-up of Lower Dose Dasatinib (50 Mg Daily) as Frontline Therapy in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia.” Cancer (0008543X) 126, no. 1 (January 2020): 67–75. doi:10.1002/cncr.32504.
    • Vancouver/ICMJE:
      Naqvi K, Jabbour E, Skinner J, Anderson K, Dellasala S, Yilmaz M, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer (0008543X) [Internet]. 2020 Jan [cited 2020 Sep 25];126(1):67–75. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=140299210